SHARx Warns PBM Rebate Reform May Move Money Without Lowering Employer Costs

As regulators push for greater transparency in pharmacy benefit management (PBM), SHARx warns that reforms aimed at PBM rebates may simply redistribute funds without lowering overall costs for employers. The company advises stakeholders to look beyond promises of rebate pass-through and assess whether total pharmacy expenses are truly decreasing.

The push for increased transparency in the PBM industry, driven by regulatory bodies, is prompting a re-evaluation of rebate structures. SHARx asserts that employers must determine if these changes lead to tangible savings in their total drug spending. The focus should be on the net effect on the bottom line, not solely on the visibility of rebates.

SHARx emphasizes that employers should critically evaluate PBMs based on their ability to manage the complete spectrum of pharmacy costs, including drug acquisition prices, administrative fees, and formulary management. A singular focus on rebate transparency could overlook inefficiencies elsewhere in the pharmacy benefit chain.

The company encourages employers and other parties to demand clear evidence from their PBM partners demonstrating how these reforms translate into reduced total expenditures. Increased transparency is a necessary first step, but the ultimate goal remains the containment of overall pharmacy costs, according to SHARx.